Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

Abstract Background Uncontrolled bleeding after cardiac surgery can be life-threatening. Factor eight inhibitor bypassing activity (FEIBA) is a prothrombin complex concentrate empirically used as rescue therapy for correction of refractory bleeding diathesis post-cardiopulmonary bypass (CPB). FEIBA...

Full description

Bibliographic Details
Main Authors: Valerie A. Sera, Ann E. Stevens, Howard K. Song, Victor M. Rodriguez, Frederick A. Tibayan, Miriam M. Treggiari
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Pilot and Feasibility Studies
Subjects:
Adult anesthesia
Anesthetics
Cardiac surgery
Bleeding disorders
Coagulopathies
Hematology
Online Access:https://doi.org/10.1186/s40814-021-00873-5

Internet

https://doi.org/10.1186/s40814-021-00873-5

Similar Items